Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775657 | 0.87 | CALM1 (0.58) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL12232284 | 0.87 | CA2 (0.48) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL12775648 | 0.87 | CALM1 (0.50) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL5114730 | 0.86 | CA2 (0.61) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL12446453 | 0.86 | KDM4E (0.47) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL5114907 | 0.84 | CA2 (0.59) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL9917303 | 0.84 | CA2 (0.44) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL11258047 | 0.84 | CA2 (0.59) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL9917308 | 0.84 | CRHBP (0.47) | CA2CYP19A1ATMKDM4EALDH1A1 | |
| SCHEMBL11220193 | 0.84 | CA2 (0.59) | CA2CYP19A1ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813550-A | Photosensitive surface treating agent, laminate, transistor, pattern forming method, and method for manufacturing transistor | 株式会社尼康 | 2024-04-02 | — | — | CN | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | HOLOSMEDIC (KR) | 2023-01-19 | — | — | US | disclosed |
| US-10927088-B2 | Thymoquinone derivatives for treatment of cancer | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2021-02-23 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | CA2 1125/4885CYP19A1 1903/4885ATM 2866/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CA2 2623/4885CYP19A1 4531/4885ATM 1956/4885 |
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | CA2 351/4885CYP19A1 2504/4885ATM 1011/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA2 2623/4885CYP19A1 4531/4885ATM 1956/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CA2 1511/4885CYP19A1 2789/4885ATM 2210/4885 |
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | CA2 2592/4885CYP19A1 2558/4885ATM 363/4885 |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | TNNC1, TNNI3, PYGM | CA2 228/4885CYP19A1 3115/4885ATM 4600/4885 |
| US-10927088-B2 | Thymoquinone derivatives for treatment of cancer | TYMS, TYMP, NQO1 | CA2 4483/4885CYP19A1 444/4885ATM 1106/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | CA2 2222/4885CYP19A1 306/4885ATM 4598/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | CA2 4547/4885CYP19A1 413/4885ATM 3564/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | CA2 4593/4885CYP19A1 1540/4885ATM 362/4885 |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | GABRE, SLC6A1, GABBR1 | CA2 322/4885CYP19A1 630/4885ATM 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.